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Of all diagnosed pregnancies, 10 -15% end in spontaneous mis carriage (SM). [1] Chromosomal abnormalities are the most common cause, more than 50% of aborted fetuses in the first trimester showing numerical abnormalities including trisomies, X monosomies and tripoidies. Aneuploidies become less prevalent as pregnancy progresses (30% in the second trimester), because most abnormal fetuses have miscarried earlier. A number of other factors (maternal factors, infections, etc.) may also play a role. [2, 3] Cytogenetic analysis of fetal tissue after SM is recommended for prognostic and diagnostic purposes, and to give a better estimate of the risk of recurrence in future pregnancies. It enables detection of possible unbalanced segregation associated with advanced maternal age or the presence of balanced structural rearrangement. [3, 4] Conventional karyotyping has been the gold standard for the cytogenetic analysis of products of SM. However, SM products in the first trimester are often collected at advanced stages of maceration as a result of tissue disintegration of the dead fetus in utero, which may cause significant DNA damage, or are haemorrhagic samples contaminated with maternal blood. Because karyotype analysis requires cell culture to obtain metaphase spreads, the poor quality of SM products often means that it is impossible to obtain a result because of culture failure, or that results are invalid due to maternal cell contamination (MCC).
Some molecular cytogenetic approaches such as FISH (fluorescence in situ hybridisation), MLPA (multiplex ligation probe amplification) and QF-PCR (quantitative fluorescence-polymerase chain reaction) have been described as valuable in the cytogenetic analysis of SM products. [5] [6] [7] Performed within 24 -48 hours, as opposed to weeks for karyotyping, these do not require cell culture, and DNA can be analysed directly after it is extracted. However, while it is possible to investigate several regions with FISH, the number of regions that can be explored with QF-PCR is limited, and MLPA requires the use of two commercial kits to invesigate subtelomere regions. [8] An additional approach is array-comparative genomic hybridisation (CGH), which has a better diagnostic yield than conventional karyotyping in the screening of products of conception (POC) [1] but with the disadvantage of high cost.
A new rapid method for the detection of whole-chromosome aneuploidies, based on a BACs-On-Beads TM technology (Perkin Elmer, Finland), has recently been introduced. Two assays are available, Prenatal BoBs TM for the detection of trisomy 13, 18, and 21 and the most frequent syndromes associated with microdeletions, and KaryoLite BoBs TM , which can detect aneuploidy in all chromosomes by quantifying the proximal and terminal regions of each chromosome arm. Prenatal BoBs TM has been shown to be a robust technology for the prenatal investigation of fetuses with or without abnormalities on ultrasound, [5, 9] whereas KaryoLite BoBs TM has been found clinically useful for the investigation of SM products. [10] Since September 2012, Prenatal BoBs TM has been used for prenatal diagnosis in the routine clinical setting in the Medical Cytogenetic Service of the University Hospital of Clermont-Ferrand (France). We describe our clinical experience of the screening of SM products collected at the university hospitals of Clermont-Ferrand and Sidi Bel Abbès (Western Algeria) using Prenatal BoBs 
Results. Prenatal BoBs
TM identified one trisomy 21 and one deletion of 17p13.3. Furthermore, it provided a conclusive result in cases of culture failure (n=38) and in samples with macerated tissue (n=19). The overall failure rate was 11.4%.
Conclusions. Prenatal BoBs
TM is a promising technology that represents a fast, sensitive and robust alternative to routine screening for chromosomal abnormality in products of SM. Furthermore, it overcomes the limitations of conventional karyotyping and current molecular cytogenetic techniques.
Patients and methods

Biological samples and DNA extraction
Seventeen POC were collected after SMs in the maternity department of the Hassani Abdelkader University Hospital of Sidi Bel Abbès, and 60 additional samples were collected at the University Hospital of Clermont-Ferrand after medical abortion due to suspicion of a molar pregnancy (n=1), spontaneous abortion (n=8) or fetal death in utero (n=51). Samples included chorionic villi from products of curettage (n=19), placenta (n=12), amniotic cells (n=9) and biopsy specimens (n=37).
Gestational ages ranged from 5 to 40 weeks (mean 21.5): 17 specimens were from the first trimester (5 -12 weeks), 35 from the second trimester (13 -24 weeks) and 25 from the third trimester (25 -41 weeks). Women who had SMs were between 19 and 43 years of age (mean 30.3), 23.3% being of advanced maternal age (≥35). All women provided written consent.
Placental chorionic villi from maternal decidua, blood clots and mucus were dissected under a dissecting microscope into fragments a few millimetres in size. DNA was obtained from chorionic villus cells, amniotic cells or fetal skin fibroblasts without cell culture using the QIAamp DNA Mini Kit (Qiagen, Germany).
Prenatal BoBs™ assay
All the samples collected were analysed using the Prenatal BoBs TM kit. Fig. 1 shows the main steps of the assay. Prenatal BoBs TM is a multiplex bead-based suspension array technology designed for gain-and-loss screening of chromosomes 13, 18, 21, X and Y and nine targeted microdeletion regions. It uses the Luminex TM xMAP TM technology (Luminex Corp., USA), a multiplexing technology utilising polystyrene beads approximately 5 μm in diameter that have been impregnated with a specific ratio of two different fluorescent dyes. Ten concentrations of both dyes were used, and a range of >100 different dye/bead combinations with distinct fluorescent signatures or spectral addresses that can be identified through excitation of the impregnated dyes when read by the Luminex TM analyser was created. In Prenatal BoBs Where deletions or duplications were present, probe ratios were outside the normal expected ratio range determined by the software for each sample.
The contents of the Prenatal BoBs TM kit were sufficient for 96 reactions. This assay was used for the rapid detection of gains and losses of DNA in 75 regions, including aneuploidies of chromosomes 13, 18, 21, X and Y, as well as gains and losses in nine microdeletion syndrome regions that are often associated with genetic disorders. Eighty-three BAC probes were used in the Prenatal BoBs X and Y, four to eight each for the nine well-defined target loci, and six autosomal controls, as shown in Table 1 . Selection of the nine microdeletion syndrome regions was based on their association with chromosomal disorders with a relatively high prevalence, and syndromes in which the deletion was the major mechanism underlying the pathology. Deletions of these regions are generally not detectable or may be missed by conventional karyotyping. The syndromes have well-described phenotypes and known clinical significance. [11] 
Results
We attempted analysis using Prenatal BoBs TM in 70 of the 77 samples collected. Of the remaining seven, six were empty gestational sacs, haemorrhagic samples with MCC or macerated samples with absence of chorionic villi; the last sample was excluded owing to a low DNA amount after DNA extraction (<5 ng/μL).
Cytogenetic analysis using Prenatal BoBs TM gave a conclusive result for 62 of the 70 samples (88.6%). Failure to deliver a result in the remaining eight cases (11.4%) was due to poor DNA quality. Of the 62 samples, 60 were considered normal (96.8%) and two had abnormal results (3.2%) ( Table 2) : one trisomy 21 (intrauterine fetal death at 11 weeks' gestation), and a deletion of 17p13.3 (Miller-Dieker syndrome, MDS) (Fig. 2) .
Standard karyotyping was not attempted in 26 samples, 19 of which were too macerated for cell culture. Karyotyping failed in 38 samples because of absence of cell proliferation and microbial contamination in the cell cultures. Thirteen samples had normal karyotypes.
Trisomy 21 was detected in a female fetus who died in utero at 11 weeks' gestation. At autopsy, the fetus was found to have a hygroma and generalised subcutaneous oedema. As the cell culture failed, we could not determine whether the trisomy was total or partial.
The deletion of 17p13.3 (MDS) was identified in a female fetus who died in utero at 38 weeks' gestation. MDS is characterised by a developmental defect of the brain (type 1 lissencephaly), which is caused by incomplete neuronal migration. This microdeletion syndrome is also characterised by distinctive facial features and other congenital malformations. Serum markers in the first and second trimester were normal and the second ultrasound scan revealed a single umbilical artery. At autopsy, the fetus was found to be hypotrophied and short in length (<25th percentile) and to have a decreased head circumference (<3rd percentile). However, there were no facial dysmorphic features or cardiac, pulmonary or renal abnormalities. Neuroanatomical examination did not show lissencephaly. FISH analysis showed that the LIS1 gene, monosomy of which is responsible for MDS, was not deleted. The deletion was characterised further by array genomic comparative hybridisation (4 × 180K, Agilent, USA), which showed a deletion of 2.3 Mb encompassing 40 genes. This deletion, which is not typical of the MDS, was probably responsible for the short stature of the fetus, but the fact that the single umbilical artery could have contributed to death could not be excluded.
Discussion
Prenatal BoBs TM is a recently developed molecular cytogenetic screening tool for the most common aneuploidies (chromosomes 13, 18, 21, X and Y) and the nine most frequent microdeletion syndromes found in POC, which are not detectable or may be missed by conventional karyotyping. This rapid targeted assay is dependent on DNA extraction and does not require live or intact cells, and represents an interesting alternative to conventional cytogenetics that require cell culture. [5, 9, 11, 12] In our study, cell culture failure prevented standard karyotype analysis of 38 samples. However, Prenatal BoBs TM provided a conclusive result in all cases, making it a useful tool for the cytogenetic analysis of POCs, especially when culture fails.
We analysed 70 DNA samples extracted from chorionic villi of products of SM, skin fibroblasts, amniotic cells and products of curretage. Eight cases were uninterpretable, giving a technical failure rate of 11.4%, which was higher than the rate of ~3% registered for prenatal screening using Prenatal BoBs TM [5, 12] and also higher than the rate of ~ 2% reported for the screening of POCs using Karyolite Bobs TM . [6, 10] These results may be explained by the fact that we had numerous samples with poor DNA quality due to advanced maceration of fetal tissue.
Among the remaining cases, Prenatal BoBs TM revealed the presence of two chromosomal abormalities: one case of trisomy 21 that could not be detected by karyotyping because of cell culture failure and was associated with advanced maternal age (42 years), a risk factor well known to increase the risk of aneuploidies, mostly trisomies, [7] and one case of microdeletion of 17p13.3 (2.3 Mb) that could not be detected by karyotyping because of its low resolution, or by Karyolite BoBs TM because of limitations in the detection of structural rearrangements. These structural rearrangements account for ~6% of abnormalities found in POC. [6] MDS is a rare malformation syndrome manifested by type I lissencephaly and characteristic facial features and associated with a microdeletion of chromosome 17pl3.3, which can be detected by high-resolution cytogenetic techniques in ~50% of cases. [13] Cytogenetic investigation of 1 599 prenatal samples using Prenatal BoBs TM revealed 11 cases of microdeletions and microduplications (0.75%), among which deletion of 22q11.2 (Di George syndrome) was the most frequent abnormality detected. [5] Prenatal BoBs TM is a targeted assay, so the loci of the genome that may have clinical relevance in an unbalanced state and that are not targeted by the probe set will go undetected. [5, 9, 11] Better coverage throughout the genome would lead to the detection of additional clinically relevant imbalances, but would also identify gains or losses of unknown or unclear clinical significance. [11, 14] Moreover, Prenatal BoBs TM has some limitations in the detection of polyploidies (triploidies and tetraploidies), [5, 9] which account for nearly 16% of abnormalities found by conventional karyotyping of POC. [6] Another disadvantage of SM products is the high rate of MCC. Only a few studies have tested the ability of Prenatal BoBs TM to identify mosaicism and MCC. It has been shown that Prenatal BoBs TM can detect mosaicism in fetal tissue at a level of 20 -40% abnormal cells or higher, [9, 15] and that MCC in the fetal tissue becomes apparent at a level of 20 -30% of normal female cells. [11] Prenatal BoBs has been described as more informative than rapid FISH and QF-PCR, which screen only frequent aneuploidies. [9] This technique also enabled us to provide rapid results with conclu sive outcomes within 24 hours of receipt of the sample, [5, 9, 11, 12] which is about half the time of fast FISH aneuploidy screening, because it is possible to interpret the profiles of several samples in few minutes. [5, 9] Furthermore, it is cheaper than other technologies that are able to detect more alterations (array-CGH), being of the same order of cost as fast FISH. [9, 12] 
Conclusion
On analysis of 77 samples of POC collected, we found the cause of fetal death in two cases using Prenatal BoBs TM technology. One of these fetuses had trisomy 21 and the other a 17p13.3 deletion, which were missed by karyotyping (owing to culture failure in one case and low resolution in the second). Prenatal BoBs TM appears to be fast, sensitive and a good alternative to other conventional technologies such as karyotyping in the routine screening of SM products, especially when tissue is damaged and macerated, preventing cell culture. In combination with other molecular approaches, use of Prenatal BoBs TM could improve detection of chromosomal abnormalities in POCs and prove helpful in parental counselling.
